Trial Profile
A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs SCB 2019 (Primary) ; Alum; CpG 1018
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SPECTRA
- Sponsors Clover Biopharmaceuticals
- 03 Jul 2023 Last checked against ClinicalTrials.gov record.
- 28 Jun 2023 Status changed from active, no longer recruiting to completed.
- 10 Feb 2023 Results (n=30137) assessing SCB-2019 over the 6-month period following 2-dose primary vaccination series in all adult participants (Greater than 18 years of age) published in the Vaccine